Nocturnal enuresis after paroxetine abrupt discontinuation: A case report

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 589-591

  Polimeni, Giovanni ^a   Grugno, Rosario ^a   Cordici, Francesco ^a   Vitetta, Antongiulio ^a   Caputi, Achille Patrizio ^b   Bramanti, Placido ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; PAROXETINE; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LETTER; MORNING DOSAGE; NOCTURNAL ENURESIS; PANIC; PRIORITY JOURNAL; SOCIAL PHOBIA; SYMPTOM; TREATMENT DURATION; MIDDLE AGED; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; FEMALE; HUMANS; MIDDLE AGED; NOCTURNAL ENURESIS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 58149129751     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181850bc2     Document Type: Letter

References (20)

1. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reup- take inhibitors compared with tricyclic anti- depressants: a meta-analysis. BMJ. 1995;310: 1433-1438.
2. Demyttenaere K, Van Ganse E, Gregoire J, et al. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int Clin Psychopharmacol. 1998; 13:11-17.
3. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psycho- pharmacol. 1996;16:356-362.
4. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br JClin Pharmacol. 1996;42: 757-763.
5. Lejoyeux M, Ades J, Mourad I, et al. Antidepressant withdrawal syndrome. CNS Drugs. 1996;5:278-292.
6. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry. 1997;58:19-22.
7. Bhanji NH, Chouinard G, Kolivakis T, et al. Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound- withdrawal phenomena. Can J Clin Pharmacol. 2006;13:e69-e74.
8. Judge R, Parry MG, Quail D, et al. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol. 2002; 17:217-225.
9. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo- controlled trial. Br J Psychiatry 2000;176: 363-368.
10. Kales A, Scharf MB, Kales JD. Rebound insomnia: a new clinical syndrome. Science. 1978;201:1039-1041.
11. Blier P, Tremblay P. Physiologic mechanism underlying the antidepressant discontinuation syndrome. J Clin Psychiatry. 2006; 67:8-13.
12. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol. 2000;15:305-318.
13. Tonini M, Messori E, Franceschetti GP, et al. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br J Pharmacol. 1994;113:1-2.
14. Gilmor M, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002;159:1702-1710.
15. Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000; 11:386-388.
16. Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf. 2002;11:271-279.
17. Polimeni G, Salvo F, Cutroneo P, et al. Venlafaxine-induced urinary incontinence resolved after switching to sertraline. Clin Neuropharmacol. 2005;28:247-248.
18. Thom DH, Nygaard IE, Calhoun EA. Urologic diseases in America project: urinary incontinence in women-national trends in hospitalizations, office visits, treatment and economic impact. JUrol. 2005;173: 1295-1301.
19. Stothers L, Thom D, Calhoun E. Urologic diseases in America project: urinary incontinence in males-demographics and economic burden. JUrol. 2005;173:1302-1308.
20. Couture JA, Valiquette L. Urinary incontinence. Ann Pharmacother. 2000;34:646-655.